Back

Do we really need aspirin?

18 March 2022 (12:51 - 13:04)
Organised by:
Congress Presentation Part of: Anti-thrombotic management in patients with acute coronary syndromes (ACS) Thrombosis, Platelets, and Coagulation ACVC Premium Access ESC Acute CardioVascular Care 2022

About the speaker

Photo
Professor Roxana Mehran

Icahn School of Medicine at Mount Sinai, New York City (United States of America)

4 More presentations in this session

Presentation thumbnail
The novel subcutaneously administered glycoprotein IIb/IIIa antagonist RUC-4 (Zalunfiban) did not cause thrombocytopenia in the phase 2a study of patients with ST-elevation myocardial infarction
Mr S. Rikken (Nieuwegein, NL)
Abstract Slides Video
Presentation thumbnail
Antiplatelet pretreatment in NSTE-ACS: do we have the answer?
Doctor P. Capranzano (Catania, IT)
Slides Video
Presentation thumbnail
Extended, standard or de-escalation antiplatelet therapy after ACS?
Professor K. Huber (Vienna, AT)
Slides Video
Presentation thumbnail
Anti-thrombotic management in patients with acute coronary syndromes - discussion.
Video

Access the full session

Session thumbnail
Anti-thrombotic management in patients with acute coronary syndromes (ACS)
Video

The Event

Event poster

ESC Acute CardioVascular Care 2022

18 March 2022 12:51 CET
You may be interested in
thumbnail
Congress Presentation
Is aspirin the preferred monotherapy after DAPT?
thumbnail
Congress Session
Oral antiplatelet therapy after acute coronary syndromes: how to choose the best regimen and the optimum duration
thumbnail
Congress Session
Novel antiplatelet approaches following acute coronary syndromes or percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources